High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells

Assay and Drug Development Technologies

Volumn 12, Issue 1, 2014, Pages 43-54

  Sirenko, Oksana ^a   Hesley, Jayne ^a   Rusyn, Ivan ^b   Cromwell, Evan F ^a  

^a MOLECULAR DEVICES CORPORATION   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENT DYE; PHOSPHOLIPID;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL ADHESION; CELL ASSAY; CELL CULTURE; CELL SHAPE; CELL SPREADING; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CURVE FITTING; CYTOSKELETON; DRUG SAFETY; HIGH CONTENT ASSAY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; LIPID STORAGE; LIPIDOSIS; LIVER CELL; LIVER TOXICITY; MITOCHONDRIAL MEMBRANE POTENTIAL; NUCLEAR SHAPE; PHENOTYPE; PLURIPOTENT STEM CELL; RISK ASSESSMENT;

APOPTOSIS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PHARMACEUTICAL PREPARATIONS; PLURIPOTENT STEM CELLS;

EID: 84896696047     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2013.520     Document Type: Article

References (33)

1. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-715.
2. Gunawan BK, Kaplowitz N: Mechanisms of drug-induced liver disease. Clin Liver Dis 2007;11:459-475.
3. Stine JG, Lewis JH: Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol 2011;7:875-890.
4. Corsini A, Ganey P, Ju C, et al.: Current challenges and controversies in drug-induced liver injury. Drug Saf 2012;35:1099-1117.
5. Lee WM: Acute liver failure in the United States. Semin Liver Dis 2003;23:217-226.
6. Lee WM: Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-485.
7. Hartung T, Daston G: Are in vitro tests suitable for regulatory use? Toxicol Sci 2009;111:233-237.
8. Hartung T: A toxicology for the 21st century-mapping the road ahead. Toxicol Sci 2009;109:18-23.
9. Krewski D, Westphal M, Al Zoughool M, Croteau MC, Andersen ME: New directions in toxicity testing. Annu Rev Public Health 2011;32:161-178.
10. Hartung T: Toxicology for the Twenty-First Century. Nature 2009;460:208-212.
11. Soldatow VY, LeCluyse EL, Griffith LG, Rusyn I: In vitro models for liver toxicity testing. Toxicol Res 2013;2:23-39.
12. Groneberg DA, Grosse-Siestrup C, Fischer A: In vitro models to study hepatotoxicity. Toxicol Path 2002;30:394-399.
13. Wormser U, Ben-Zakine S: The liver slice system: an in vitro acute toxicity test for assessment of hepatotoxins and their antidotes. Toxicol In Vitro 1990;4:449-451.
14. Elferink MG, Olinga P, van Leeuwen EM, et al.: Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol 2011;253:57-69.
15. Gomez-Lechon MJ, Castell JV, Donato MT: The use of hepatocytes to investigate drug toxicity. Methods Mol Biol 2010;640:389-415.
16. Rodrigues RM, Bouhifd M, Bories G, Sacco MG, Gribaldo L, Fabbri M, Coecke S, Whelan MP: Assessment of an automated in vitro basal cytotoxicity test system based on metabolically-competent cells. Toxicol In Vitro 2013;27:760-767.
17. Anson BD, Kolaja KL, Kamp TJ: Opportunities for use of human iPS cells in predictive toxicology. Clin Pharmacol Ther 2011;89:754-758.
18. Schweikart K, Guo L, Shuler Z, et al.: The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity. Toxicol In Vitro 2013;27:745-751.
19. Jehle J, Ficker E, Wan X, et al.: Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells. Br J Pharmacol 2013;168:1215-1229.
20. Harris K, Aylott M, Cui Y, Louttit JB, McMahon NC, Sridhar A: Comparison of electrophysiological data from human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) to functional pre-clinical safety assays. Toxicol Sci 2013;134:412-426.
21. Medine CN, Lucendo-Villarin B, Storck C, et al.: Developing high-fidelity hepatotoxicity models from pluripotent stem cells. Stem Cells Trans Med 2013;2:505-509.
22. Rana P, Anson B, Engle S, Will Y: Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. Toxicol Sci 2012;130:117-131.
23. Reynolds JG, Geretti E, Hendriks BS, et al.: HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Appl Pharmacol 2012;262:1-10.
24. Thomas N: High-content screening: a decade of evolution. J Biomol Screen 2010;5:1-9.
25. O'Brien PJ, Irwin W, Diaz D, et al.: High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high-content screening. Arch Toxicol 2006;80:580-604.
26. Mennecozzi M, Landesmann B, Harris GA, Liska R, Welan M: Hepatotoxicity screening taking a mode-of-action approach using HepaRG cells and HCA. ALTEX Proc 2012;1:193-204.
27. Zhang JH, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
28. United States Environmental Protection Agency: Benchmark Dose Technical Guidance. U.S. EPA, Washington, DC, 2012.
29. Reif DM, Sypa M, Lock EF, et al.: ToxPi GUI: an interactive visualization tool for transparent integration of data from diverse sources of evidence. Bioinformatics 2013;29:402-403.
30. Hu K, Yu J, Suknuntha K, et al.: Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood 2011;117:e109-e119.
31. Chen G, Gulbranson DR, Hou Z, et al.: Chemically defined conditions for human iPSC derivation and culture. Nat Methods 2011;8:424-429.
32. Mann DA, Einhorn S, Block K, et al.: Human iPSC-derived hepatocytes: functional model tissue for in vitro predictive metabolism, toxicity, and disease modeling. Gen Eng Biotech News 2013;33:28-29.
33. Tone S, Sugimoto K, Tanda K, et al.: Three distinct stages of apoptotic nuclear condensation revealed by time-lapse imaging, biochemical and electron microscopy analysis of cell-free apoptosis. Exp Cell Res 2007;313:3635-3644.